Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S25-S37 , April 2003

Hypothesis for a Common Basis for Neuroprotection in Glaucoma and Alzheimer's Disease: Anti-Apoptosis by Alpha-2-Adrenergic Receptor Activation

  • William Tatton, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Dr. William G. Tatton, Department of Neurology, Annenberg 14–70, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, New York 10029, USA
    • Departments of Neurology, Mount Sinai School of Medicine, New York, NY USA
    • Departments of Ophthalmology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • David Chen

      Affiliations

    • Departments of Neurology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • Ruth Chalmers-Redman, PhD

      Affiliations

    • Departments of Neurology, Mount Sinai School of Medicine, New York, NY USA
    • ,
  • Larry Wheeler, PhD

      Affiliations

    • Allergan Laboratories, Irvine, CA, USA
    • ,
  • Ralph Nixon, MD, PhD

      Affiliations

    • Nathan-Kline Institute For Psychiatric Research, Orangeburg, NY USA
    • ,
  • Nadine Tatton, PhD

      Affiliations

    • Departments of Neurology, Mount Sinai School of Medicine, New York, NY USA

References 

  1. Adamec E, Vonsattel JP, Nixon RA. DNA strand breaks in Alzheimer's disease. Brain Res. 1999;849:67–77
  2. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 2001;913:133–139
  3. Anderson AJ, Su JH, Cotman CW. DNA damage and apoptosis in Alzheimer's disease (colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay). J Neurosci. 1996;16:1710–1719
  4. Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol. 2002;18:25–51
  5. Arai H, Kosaka K, Iizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem. 1984;43:388–393
  6. Avila J, Lim F, Moreno F, et al.  Tau function and dysfunction in neurons (its role in neurodegenerative disorders). Mol Neurobiol. 2002;25:213–231
  7. Bamberger ME, Landreth GE. Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist. 2002;8:276–283
  8. Baptiste DC, Hartwick AT, Jollimore CA, et al.  Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci. 2002;43:2666–2676
  9. Basanez G, Nechushtan A, Drozhinin O, et al.  Bax, but not Bcl-x(L), decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci USA. 1999;96:5492–5497 Proceedings of the National Academy of Sciences of the United States of America
  10. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002;47:165–168
  11. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death (Alzheimer's disease and Parkinson's disease). Am J Ophthalmol. 2002;133:135–137
  12. Bazan NG, Palacios-Pelaez R, Lukiw WJ. Hypoxia signaling to genes (significance in Alzheimer's disease). Mol Neurobiol. 2002;26:283–298
  13. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal degeneration in the macula of patients with Alzheimer's disease. Ann NY Acad Sci. 1991;640:44–46
  14. Bommakanti RK, Vinayak S, Simonds WF. Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits. J Biol Chem. 2000;275:38870–38876
  15. Bondareff W, Mountjoy CQ, Roth M. Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet. 1981;1:783–784
  16. Bondareff W, Mountjoy CQ, Roth M, et al.  Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord. 1987;1:256–262
  17. Brenner C, Cadiou H, Vieira HL, et al.  Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene. 2000;19:329–336
  18. Busch C, Bohl J, Ohm TG. Spatial, temporal and numeric analysis of Alzheimer changes in the nucleus coeruleus. Neurobiol Aging. 1997;18:401–406
  19. Cande C, Cohen I, Daugas E, et al.  Apoptosis-inducing factor (AIF) (a novel caspase-independent death effector released from mitochondria). Biochimie. 2002;84:215–222
  20. Carter J, Lippa CF. Beta-amyloid, neuronal death and Alzheimer's disease. Curr Mol Med. 2001;1:733–737
  21. Chalmers-Redman R, Elstner MQ, Mammen M, Tatton WG. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis by inducing new protein synthesis that maintains mitochondrial pore closure. ICER Abstracts. 2001;14:257
  22. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol. 1989;287:373–392
  23. Chan-Palay V, Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J Comp Neurol. 1989;287:357–372
  24. Chao HM, Osborne NN. Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res. 2001;904:126–136
  25. Chen G, Goeddel DV. TNF-R1 signaling (a beautiful pathway). Science. 2002;296:1634–1635
  26. Chen RW, Saunders PA, Wei H, et al.  Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis (evidence that GAPDH is upregulated by p53). J Neurosci. 1999;19:9654–9662
  27. Chen Z, Jia W, Kaufman PL, Cynader M. Immunohistochemical localization of dopamine-beta-hydroxylase in human and monkey eyes. Curr Eye Res. 1999;18:39–48
  28. Cotman CW, Whittemore ER, Watt JA, et al.  Possible role of apoptosis in Alzheimer's disease. Ann NY Acad Sci. 1994;747:36–49
  29. Coull JT. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. Drugs Aging. 1994;5:116–126
  30. Cross AJ, Crow TJ, Johnson JA, et al.  Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. J Neurol Sci. 1984;64:109–117
  31. Daugas E, Nochy D, Ravagnan L, et al.  Apoptosis-inducing factor (AIF) (a ubiquitous mitochondrial oxidoreductase involved in apoptosis). FEBS Lett. 2000;476:118–123
  32. Davies DC, McCoubrie P, McDonald B, Jobst KA. Myelinated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol. 1995;79:596–600
  33. de la Monte SM, Sohn YK, Ganju N, Wands JR. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest. 1998;78:401–411
  34. de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci. 1997;152:73–83
  35. Deibel MR, Coleman MS. Biochemical properties of purified human terminal deoxynucleotidyltransferase. J Biol Chem. 1980;255:4206–4212
  36. Demeester N, Baier G, Enzinger C, et al.  Apoptosis induced in neuronal cells by C-terminal amyloid beta-fragments is correlated with their aggregation properties in phospholipid membranes. Mol Membr Biol. 2000;17:219–228
  37. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002;16:33–45
  38. Dkhissi O, Chanut E, Wasowicz M, et al.  Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci. 1999;40:990–995
  39. Donello JE, Padillo EU, Webster ML, et al.  alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296:216–223
  40. Dragunow M, Faull RL, Lawlor P, et al.  In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 1995;6:1053–1057
  41. Elena PP, Kosina-Boix M, Moulin G, Lapalus P. Autoradiographic localization of beta-adrenergic receptors in rabbit eye. Invest Ophthalmol Vis Sci. 1987;28:1436–1441
  42. Engidawork E, Gulesserian T, Yoo BC, et al.  Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 2001;281:84–93
  43. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol. 2000;20:929–935
  44. Feinstein DL, Heneka MT, Gavrilyuk V, et al.  Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002;41:357–365
  45. Ferrer I, Puig B, Krupinsk J, et al.  Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathol (Berl). 2001;102:121–131
  46. Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders (potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease). Biol Psychiatry. 1999;46:1243–1252
  47. Fukuhara Y, Takeshima T, Kashiwaya Y, et al.  GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+-induced apoptosis. Neuroreport. 2001;12:2049–2052
  48. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33–44
  49. German DC, White CL, Sparkman DR. Alzheimer's disease (neurofibrillary tangles in nuclei that project to the cerebral cortex). Neuroscience. 1987;21:305–312
  50. Gold MS, Dastmalchi S, Levine JD. Alpha 2-adrenergic receptor subtypes in rat dorsal root and superior cervical ganglion neurons. Pain. 1997;69:179–190
  51. Golubnitschaja-Labudova O, Liu R, Decker C, et al.  Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res. 2000;21:867–876
  52. Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases (fashion, fiction, and facts). Brain Pathol. 2002;12:385–390
  53. Grosse F, Manns A. Terminal deoxyribonucleotidyl transferase (EC 2.7.7.31). In:  Burrell F editors. Methods in Molecular Biology. Totowa, NJ: Humana Press, Inc; 1993;p. 95–105
  54. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex (another view). Biochimie. 2002;84:153–166
  55. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease (progress and problems on the road to therapeutics). Science. 2002;297:353–356
  56. Hedges TR, Perez Galves R, Speigelman D, et al.  Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthalmol Scand. 1996;74:271–275
  57. Heneka MT, Galea E, Gavriluyk V, et al.  Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation (implications for Alzheimer's disease). J Neurosci. 2002;22:2434–2442
  58. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315:485–487
  59. Huang Y, Gil DW, Vanscheeuwijck P, et al.  Localization of alpha 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci. 1995;36:2729–2739
  60. Hurvitz LM, Kaufman PL, Robin AL, et al.  New developments in the drug treatment of glaucoma. Drugs. 1991;41:514–532
  61. Ichimiya Y, Arai H, Kosaka K, Iizuka R. Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer-type dementia. Acta Neuropathol. 1986;70:112–116
  62. Ishimoto I, Kiyama H, Hamano K, et al.  Co-localization of adrenergic receptors and vitamin-D-dependent calcium- binding protein (calbindin) in the dopaminergic amacrine cells of the rat retina. Neurosci Res. 1989;7:257–263
  63. Ishitani R, Kimura M, Sunaga K, et al.  An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther. 1996;278:447–454
  64. Ishitani R, Sunaga K, Hirano A, et al.  Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem. 1996;66:928–935
  65. Johnson EM. Possible role of neuronal apoptosis in Alzheimer's disease. Neurobiol Aging. 1994;15:S187–S189
  66. Justino L, Kergoat M, Bergman H, et al.  Neuroretinal function is normal in early dementia of the Alzheimer type. Neurobiol Aging. 2001;22:691–695
  67. Kalaria RN, Andorn AC. Adrenergic receptors in aging and Alzheimer's disease (decreased alpha 2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex). Neurobiol Aging. 1991;12:131–136
  68. Kalaria RN, Andorn AC, Tabaton M, et al.  Adrenergic receptors in aging and Alzheimer's disease (increased beta 2-receptors in prefrontal cortex and hippocampus). J Neurochem. 1989;53:1772–1781
  69. Kalaria RN, Stockmeier CA, Harik SI. Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci Lett. 1989;97:203–208
  70. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci. 2002;5(Suppl):1039–1042
  71. Kergoat H, Kergoat MJ, Justino L, et al.  An evaluation of the retinal nerve fiber layer thickness by scanning laser polarimetry in individuals with dementia of the Alzheimer type. Acta Ophthalmol Scand. 2001;79:187–191
  72. Kerrigan LA, Zack DJ, Quigley HA, et al.  TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031–1035
  73. Kim HS, Lee JH, Lee JP, et al.  Amyloid beta peptide induces cytochrome c release from isolated mitochondria. Neuroreport. 2002;13:1989–1993
  74. Kitamura Y, Shimohama S, Kamoshima W, et al.  Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 1998;780:260–269
  75. Kohler C, Orrenius S, Zhivotovsky B. Evaluation of caspase activity in apoptotic cells. J Immunol Methods. 2002;265:97–110
  76. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59:1693S–1700S
  77. Korsmeyer SJ, Wei MC, Saito M, et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7:1166–1173
  78. Kugler S, Straten G, Kreppel F, et al.  The X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo. Cell Death Differ. 2000;7:815–824
  79. Lafarga M, Andres MA, Calle E, Berciano MT. Reactive gliosis of immature Bergmann glia and microglial cell activation in response to cell death of granule cell precursors induced by methylazoxymethanol treatment in developing rat cerebellum. Anat Embryol (Berl). 1998;198:111–122
  80. Lafuente MP, Villegas-Perez MP, Sobrado-Calvo P, et al.  Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42:2074–2084
  81. Lassmann H, Bancher C, Breitschopf H, et al.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 1995;89:35–41
  82. Leist M, Jaattela M. Four deaths and a funeral (from caspases to alternative mechanisms). Nat Rev Mol Cell Biol. 2001;2:589–598
  83. Li BM, Kubota K. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to a visual discrimination task with GO and NO-GO performances in monkeys. Neurosci Res. 1998;31:83–95
  84. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001;412:95–99
  85. Li WP, Chan WY, Lai HW, Yew DT. Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients. J Mol Neurosci. 1997;8:75–82
  86. Linner E, Popovic V, Gottfries CG, et al.  The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand. 2001;79:283–285
  87. Liu W, Alreja M. Norepinephrine inhibits neurons of the intermediate subnucleus of the lateral septum via alpha2-adrenoceptors. Brain Res. 1998;806:36–54
  88. Liu XS, Kim CN, Yang J, et al.  Induction of apoptotic program in cell-free extracts (Requirement for dATP and cytochrome c). Cell. 1996;86:147–157
  89. Loeffler M, Daugas E, Susin SA, et al.  Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. Faseb J. 2001;15:758–767
  90. Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci. 1995;36:24–31
  91. MacGibbon GA, Lawlor PA, Sirimanne ES, et al.  Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res. 1997;750:223–234
  92. Maier C, Steinberg GK, Sun GH, et al.  Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology. 1993;79:306–312
  93. Mann DM, Yates PO, Marcyniuk B. A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1984;47:201–203
  94. Mann DM, Yates PO, Marcyniuk B. A comparison of nerve cell loss in cortical and subcortical structures in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1986;49:310–312
  95. Mann DM, Yates PO, Marcyniuk B. Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett. 1985;56:51–55
  96. Marcyniuk B, Mann DM, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci. 1986;76:335–345
  97. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001;2:63–67
  98. Matthews KL, Chen CP, Esiri MM, et al.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002;51:407–416
  99. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al.  Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077–1087
  100. Mielke K, Herdegen T. JNK and p38 stress kinases—degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol. 2000;61:45–60
  101. Migheli A, Cavalla P, Marino S, Schiffer D. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol. 1994;53:606–616
  102. Milner TA, Rosin DL, Lee A, Aicher SA. Alpha2A-adrenergic receptors are primarily presynaptic heteroreceptors in the C1 area of the rat rostral ventrolateral medulla. Brain Res. 1999;821:200–211
  103. Mittag TW, Danias J, Pohorenec G, et al.  Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2000;41:3451–3459
  104. Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev. 2002;54:1627–1656
  105. Morfini G, Pigino G, Beffert U, et al.  Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med. 2002;2:89–99
  106. Morishima-Kawashima M, Ihara Y. Alzheimer's disease (beta-Amyloid protein and tau). J Neurosci Res. 2002;70:392–401
  107. Morrison JC, Nylander KB, Lauer AK, et al.  Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Invest Ophthalmol Vis Sci. 1998;39:526–531
  108. Mountjoy CQ, Bondareff W. Comparison of counts of neurons in the locus coeruleus made from serial sections and from a single section at the centre of the nucleus. Can J Neurol Sci. 1986;13:480–482
  109. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 2002;25:22–26
  110. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000;256:12–18
  111. Nagy ZS, Esiri MM. Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol Aging. 1997;18:565–571
  112. Narita M, Shimizu S, Ito T, et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA. 1998;95:14681–14686
  113. Negoescu A, Lorimier P, Labat-Moleur F, et al.  In situ apoptotic cell labeling by the TUNEL method (improvement and evaluation on cell preparations). J Histochem Cytochem. 1996;44:959–968
  114. Nesselhut T, Osborne NN. Is noradrenaline a major catecholamine in the bovine retina?. Neurosci Lett. 1982;28:41–45
  115. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma (an update of the molecular pathways involved in cell death). Surv Ophthalmol. 1999;43(Suppl 1):S151–S161
  116. Nicotera P. Apoptosis and age-related disorders (role of caspase-dependent and caspase-independent pathways). Toxicol Lett. 2002;127:189–195
  117. Niikura T, Hashimoto Y, Tajima H, Nishimoto I. Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res. 2002;70:380–391
  118. Nishimura T, Akiyama H, Yonehara S, et al.  Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res. 1995;695:137–145
  119. Nishizaki K, Yoshino T, Orita Y, et al.  TUNEL staining of inner ear structures may reflect autolysis, not apoptosis. Hear Res. 1999;130:131–136
  120. Ohm TG, Hamker U, Cedazo-Minguez A, et al.  Apolipoprotein E and beta A4-amyloid (signals and effects). Biochem Soc Symp. 2001;67:121–129
  121. Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41:84–88
  122. Osborne NN. Agonist-induced stimulation of cAMP in the lens (presence of functional beta-receptors). Exp Eye Res. 1991;52:105–106
  123. Osborne NN. Binding of (-)[3H]noradrenaline to bovine membrane of the retina. Evidence for the existence of alpha. 1982;2-receptors.(Vision Res 22):1401–1407
  124. Osborne NN. Neuromediators and their receptors (adrenergic and endothelin types) in the eye. Therapie. 1993;48:549–558
  125. Osborne NN. Noradrenaline, a transmitter candidate in the retina. J Neurochem. 1981;36:17–27
  126. Osborne NN, Cazevieille C, Carvalho AL, et al.  In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 1997;751:113–123
  127. Osborne NN, DeSantis L, Bae JH, et al.  Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res. 1999;69:331–342
  128. Osborne NN, Patel S. The presence of dopamine-beta-hydroxylase in the vertebrate retina. Neurochem Int. 1985;7:51–56
  129. Parisi V, Restuccia R, Fattapposta F, et al.  Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol. 2001;112:1860–1867
  130. Parone PA, James D, Martinou JC. Mitochondria (regulating the inevitable). Biochimie. 2002;84:105–111
  131. Pascual J, Grijalba B, Garcia-Sevilla JA, et al.  Loss of high-affinity alpha 2-adrenoceptors in Alzheimer's disease (an autoradiographic study in frontal cortex and hippocampus). Neurosci Lett. 1992;142:36–40
  132. Perry EK, Perry RH. A review of neuropathological and neurochemical correlates of Alzheimer's disease. Dan Med Bull. 1985;32(Suppl 1):27–34
  133. Perry G, Cash AD, Smith MA. Alzheimer Disease and oxidative stress. J Biomed Biotechnol. 2002;2:120–123
  134. Perry RT, Collins JS, Wiener H, et al.  The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2001;22:873–883
  135. Pimplikar SW, Abeta PP. Apoptosis and Alzheimer's disease. J Alzheimers Dis. 2002;4:39–40
  136. Quigley HA, Dunkelberger GR, Green WR. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers. Ophthalmology. 1988;95:357–363
  137. Quigley HA, Nickells RW, Kerrigan LA, et al.  Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786
  138. Quigley HA, Sanchez RM, Dunkelberger GR, et al.  Chronic glaucoma selectively damages large optic nerve fibers. Invest Ophthalmol Vis Sci. 1987;28:913–920
  139. Raina AK, Hochman A, Zhu X, et al.  Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl). 2001;101:305–310
  140. Rank KB, Pauley AM, Bhattacharya K, et al.  Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hyperphosphorylation by tau protein kinase II. FEBS Lett. 2002;514:263–268
  141. Rapoport M, Dawson HN, Binder LI, et al.  Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA. 2002;99:6364–6369
  142. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ. 2000;7:1145
  143. Roucou X, Rostovtseva T, Montessuit S, et al.  Bid induces cytochrome c-impermeable Bax channels in liposomes. Biochem J. 2002;363:547–552
  144. Ruffolo SC, Breckenridge DG, Nguyen M, et al.  BID-dependent and BID-independent pathways for BAX insertion into mitochondria. Cell Death Differ. 2000;7:1101–1108
  145. Sadun AA. The optic neuropathy of Alzheimer's disease. Metab Pediatr Syst Ophthalmol. 1989;12:64–68
  146. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology. 1990;97:9–17
  147. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med. 2002;1:1–31
  148. Samejima K, Tone S, Earnshaw WC. CAD/DFF40 nuclease is dispensable for high molecular weight DNA cleavage and stage I chromatin condensation in apoptosis. J Biol Chem. 2001;276:45427–45432
  149. Saraste A. Morphologic criteria and detection of apoptosis. Herz. 1999;24:189–195
  150. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase (nuclear translocation participates in neuronal and nonneuronal cell death). Proc Natl Acad Sci USA. 1997;94:11669–11674
  151. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv. 2000;74:281–286
  152. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans. 2001;29:684–688
  153. Scorrano L, Ashiya M, Buttle K, et al.  A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell. 2002;2:55–67
  154. Seidl R, Bajo M, Bohm K, et al.  Neuronal apoptosis inhibitory protein (NAIP)-like immunoreactivity in brains of adult patients with Down syndrome. J Neural Transm. 1999;57(Suppl):283–291
  155. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:11039–11041
  156. Selznick LA, Holtzman DM, Han BH, et al.  In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:1020–1026
  157. Serle JB, Steidl S, Wang RF, et al.  Selective alpha 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1991;109:1158–1162
  158. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem. 2000;275:12321–12325
  159. Shimizu S, Matsuoka Y, Shinohara Y, et al.  Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol. 2001;152:237–250
  160. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J Neurochem. 1987;48:1215–1221
  161. Sirover MA. New insights into an old protein (the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase). Biochim Biophys Acta. 1999;1432:159–184
  162. Smale G, Nichols NR, Brady DR, et al.  Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol. 1995;133:225–230
  163. Smeets WJ, Gonzalez A. Catecholamine systems in the brain of vertebrates (new perspectives through a comparative approach). Brain Res Brain Res Rev. 2000;33:308–379
  164. Smith MS, Schambra UB, Wilson KH, et al.  alpha 2-Adrenergic receptors in human spinal cord (specific localized expression of mRNA encoding alpha 2-adrenergic receptor subtypes at four distinct levels). Brain Res Mol Brain Res. 1995;34:109–117
  165. Stadelmann C, Deckwerth TL, Srinivasan A, et al.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol. 1999;155:1459–1466
  166. Stone LS, Broberger C, Vulchanova L, et al.  Differential distribution of alpha2A and alpha2C adrenergic receptor immunoreactivity in the rat spinal cord. J Neurosci. 1998;18:5928–5937
  167. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport. 1994;5:2529–2533
  168. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain (correlations with DNA damage, Bcl-2 expression, and brain pathology). J Neuropathol Exp Neurol. 1997;56:86–93
  169. Su JH, Zhao M, Anderson AJ, et al.  Activated caspase-3 expression in Alzheimer's and aged control brain (correlation with Alzheimer pathology). Brain Res. 2001;898:350–357
  170. Susin SA, Lorenzo HK, Zamzami N, et al.  Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441–446 [see comments]
  171. Tabira T, Chui DH, Kuroda S. Significance of intracellular Abeta42 accumulation in Alzheimer's disease. Front Biosci. 2002;7:a44–a49
  172. Tamura T, Said S, Lu W, Neufeld D. Specificity of TUNEL method depends on duration of fixation. Biotech Histochem. 2000;75:197–200
  173. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol. 2000;166:29–43
  174. Tatton NA, Hagl C, Nandor S, et al.  Apoptotic cell death in the hippocampus due to prolonged hypothermic circulatory arrest (comparison of cyclosporine A and cycloheximide on neuron survival). Eur J Cardiothorac Surg. 2001;19:746–755
  175. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neurosci. 1997;77:1037–1048
  176. Tatton NA, Maclean-Fraser A, Tatton WG, et al.  A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol. 1998;44:S142–S148
  177. Tatton NA, Rideout HJ. Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's disease. Parkinsonism Rel Disord. 1999;5:179–186
  178. Tatton NA, Tezel G, Insolia SA, et al.  In situ detection of apoptosis in normal pressure glaucoma. A preliminary examination. Surv Ophthalmol. 2001;45(Suppl 3):S268–S272 discussion S273–6
  179. Tatton W, Chalmers-Redman R, Brown D, Tatton N: Apoptosis in parkinson's disease: signals for neuronal degradation. Ann Neurol (In press)
  180. Tatton WG, Chalmers-Redman RM, Elstner M, et al.  Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm. 2000;60(Suppl):77–100
  181. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur J Ophthalmol. 2001;11(Suppl 2):S12–S22
  182. Tatton WG, Chalmers-Redman RME, Ju WJH, et al.  Propargylamines induce anti-apoptotic new protein synthesis in serum and NGF withdrawn NGF-differentiated PC12 cells. J Pharmacol Exper Ther. 2002;301:753–764
  183. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787–1794
  184. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693–8700
  185. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci. 1981;49:419–428
  186. Tortosa A, Lopez E, Ferrer I. Bcl-2 and Bax protein expression in Alzheimer's disease. Acta Neuropathol (Berl). 1998;95:407–412
  187. Trojanowski JQ, Lee VM. The role of tau in Alzheimer's disease. Med Clin North Am. 2002;86:615–627
  188. Troy CM, Salvesen GS. Caspases on the brain. J Neurosci Res. 2002;69:145–150
  189. Tsai CS, Ritch R, Schwartz B, et al.  Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol. 1991;109:199–204
  190. van Loo G, Schotte P, van Gurp M, et al.  Endonuclease G (a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation). Cell Death Differ. 2001;8:1136–1142
  191. Vickers JC. The cellular mechanism underlying neuronal degeneration in glaucoma (parallels with Alzheimer's disease). Aust NZ J Ophthalmol. 1997;25:105–109
  192. Vidal-Sanz M, Lafuente MP, Mayor S, et al.  Retinal ganglion cell death induced by retinal ischemia. Neuroprotective effects of two alpha-. 2001;2(agonists. Surv Ophthalmol 45(Suppl 3)):S261–S267 discussion S273–6
  193. Vidal-Sanz M, Lafuente MP, Mayor-Torroglosa S, et al.  Brimonidine's neuroprotective effects against transient ischaemia- induced retinal ganglion cell death. Eur J Ophthalmol. 2001;11(Suppl 2):S36–S40
  194. Vidovic M, Cohen D, Hill CE. Identification of alpha 2 adrenergic receptor gene expression in sympathetic neurones using polymerase chain reaction and in situ hybridization. Brain Res Mol Brain Res. 1994;22:49–56
  195. Vieira HL, Haouzi D, El Hamel C, et al.  Permeabilization of the mitochondrial inner membrane during apoptosis (impact of the adenine nucleotide translocator). Cell Death Differ. 2000;7:1146–1154
  196. Wadia JS, Chalmers-Redman RME, Ju WJH, et al.  Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal (time course and modification by (-)-deprenyl). J Neurosci. 1998;18:932–947
  197. Wajant H. The Fas signaling pathway (more than a paradigm). Science. 2002;296:1635–1636
  198. Wanaka A, Kiyama H, Murakami T, et al.  Immunocytochemical localization of beta-adrenergic receptors in the rat brain. Brain Res. 1989;485:125–140
  199. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999;77:312–317
  200. Weber AJ, Chen H, Hubbard WC, Kaufman PL. Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest Ophthalmol Vis Sci. 2000;41:1370–1379
  201. Wei MC, Zong WX, Cheng EH, et al.  Proapoptotic BAX and BAK (a requisite gateway to mitochondrial dysfunction and death). Science. 2001;292:727–730
  202. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(Suppl 3):S290–S294 discussion S295–6
  203. Wheeler LA, Tatton NA, Elstner MQ, et al.  Alpha 2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through Akt protein kinase B dependent new synthesis of BCL-2. ARVO Abstracts. 2001;49:2216
  204. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol. 2001;11(Suppl 2):S30–S35
  205. Winblad B, Hardy J, Backman L, Nilsson LG. Memory function and brain biochemistry in normal aging and in senile dementia. Ann NY Acad Sci. 1985;444:255–268
  206. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855
  207. Wood JP, DeSantis L, Chao HM, Osborne NN. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp Eye Res. 2001;72:79–86
  208. Xiang H, Kinoshita Y, Knudson CM, et al.  Bax involvement in p53-mediated neuronal cell death. J Neurosci. 1998;18:1363–1373
  209. Yin KJ, Lee JM, Chen SD, et al.  Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J Neurosci. 2002;22:9764–9770
  210. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65–73
  211. Yuan L, Neufeld AH. Tumor necrosis factor-alpha (a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head). Glia. 2000;32:42–50
  212. Yucel YH, Zhang Q, Gupta N, et al.  Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol. 2000;118:378–384
  213. Yucel YH, Zhang Q, Weinreb RN, et al.  Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci. 2001;42:3216–3222
  214. Zamzami N, El Hamel C, Maisse C, et al.  Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene. 2000;19:6342–6350
  215. Zou H, Henzel WJ, Liu XS, et al.  Apaf-1, a human protein homologous to C-elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405–413

PII: S0039-6257(03)00005-5

doi: 10.1016/S0039-6257(03)00005-5

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S25-S37 , April 2003

Article Tools

* Image Usage & Resolution